Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Prospective Multi-Center, Single-Arm Study of Endoscopic Ultrasound-Guided Gastroenterostomy with Lumen-Apposing Metal Stent for Gastric Outlet Obstruction from Malignant Unresectable Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV Infection (ECLIPSE 1)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025
Checking In: The Role of Sleep in Cardiovascular Health Among Men Living with HIV
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2025
A Phase 3b, open label, randomized, standard-of-care control arm, multicenter, superiority study evaluating the efficacy, safety and tolerability of injectable CAB LA + RPV LA in viremic participants living with HIV-1 (CROWN)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2025
A Phase 2 Crossover Study Of On-Demand Prep Formulations Comparing Rectal And Oral Tenofovir-Based Prep Evaluating Extended Safety, Acceptability, And Pharmacokinetics/Pharmacodynamics
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2025
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 11, 2025
Use of Blood, Tumor Tissue, and Tumor Infiltrating Lymphocyte Biospecimens for Immune Cell Profiling and Research
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 2, 2025
A Multicentre, Prospective, Open-Label, Uncontrolled Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Atenativ in Patients with Congenital Antithrombin Deficiency Undergoing Surgery Or Delivery
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 2, 2025
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 2, 2025
NRG-GU013: The Phase III `High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 6, 2025